Celgene Overview

  • Year Founded
  • 1986

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 8,852


  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $80.3B

Celgene General Information


Developer of biopharmaceutical drugs intended to treat cancer, immune and inflammatory conditions. The company markets drugs to treat multiple myeloma and a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Corporate Office
  • 86 Morris Avenue
  • Summit, NJ 07901
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Celgene Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Merger/Acquisition 20-Nov-2019 $80.3B 00.000 000.00 Completed Profitable
10. Debt - Acquisition 08-Feb-2018 00.00 00.000 Completed Profitable
9. Debt Refinancing 31-Oct-2017 000 00.000 Completed Profitable
8. Debt Refinancing 01-Aug-2017 00000 00.000 Completed Profitable
7. Debt - Acquisition 03-Aug-2015 000 00.000 Completed Profitable
6. General Corporate Purpose 06-May-2014 00.00 00.000 Completed Generating Revenue
5. General Corporate Purpose 01-Aug-2013 00.00 00.000 Completed Generating Revenue
4. Debt Refinancing 07-Aug-2012 00.00 00.000 Completed Generating Revenue
3. PIPE $12.7M Completed Profitable
2. IPO 28-Jul-1987 $12.7M $12.7M Completed Generating Revenue
To view Celgene’s complete valuation and funding history, request access »

Celgene Comparisons

HQ Location
Total Raised
Post Valuation
Developer of biopharmaceutical drugs intended to treat cancer, immune and inflammatory conditions. The company markets d
Drug Discovery
Summit, NJ
8,852 As of 2018
000.00 0000-00-00
000000&0 00.000


uis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu f
0000 000000000
Bothell, WA
0000 As of 0000
000.00 0000-00-00
000000&0 00.000


labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitati
Wilmington, DE
0000 As of 0000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Celgene Competitors (27)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Seagen Formerly VC-backed Bothell, WA 0000 00.000 000000&0 00.000
Incyte Formerly VC-backed Wilmington, DE 0000 00000 00000000000 00000
Gilead Sciences Formerly VC-backed Foster City, CA 00000 000.00 0000
Merck & Co. Corporation Rahway, NJ 00000 0000 000000000 - 0000
Emmaus Life Sciences Formerly VC-backed Torrance, CA 00 000.00 000000000 - 000.00
You’re viewing 5 of 27 competitors. Get the full list »

Celgene Patents

Celgene Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240208937-A1 Compounds and their use for treatment of hemoglobinopathies Pending 04-Nov-2022 0000000000
US-20240190890-A1 Mk2 inhibitors and uses thereof Pending 27-Oct-2022 0000000000
US-20240109881-A1 Heteroaryl compounds as ligand directed degraders of irak4 Pending 20-Jul-2022 0000000000
US-20240025851-A1 Modulators of bcl6 as ligand directed degraders Pending 28-Apr-2022 0000000000
CA-3227684-A1 Process for preparing histone demethylase inhibitors Pending 18-Aug-2021 C07D405/12
To view Celgene’s complete patent history, request access »

Celgene Board Members (18)

Name Representing Role Since
Carrie Cox Self Board Member 000 0000
Rodman Drake Celgene Board Member 000 0000
You’re viewing 2 of 18 board members. Get the full list »

Celgene Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Celgene Former Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Asseily Ventures Venture Capital Minority 000 0000 000000 0
BB Biotech Asset Manager Minority 000 0000 000000 0
CHL Medical Partners Venture Capital Minority 000 0000 000000 0
Edelson Technology Partners Venture Capital Minority 000 0000 000000 0
Ridgeback Capital Venture Capital Minority 000 0000 000000 0
To view Celgene’s complete investors history, request access »

Celgene Investments & Acquisitions (127)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Aitia 07-Jan-2020 00000 0000 0000 Drug Discovery
Oncorus 20-Dec-2019 00000 0000 000.00 Biotechnology
Cyteir Therapeutics 15-Oct-2019 00000 0000 000.00 Drug Discovery 00000 000
Anokion 11-Sep-2019 00000 0000 000.00 Drug Discovery
RAPT Therapeutics 18-Jun-2019 Later Stage VC 0000 Drug Discovery
You’re viewing 5 of 127 investments and acquisitions. Get the full list »

Celgene Subsidiaries (2)

Company Name Industry Location Founded
Acetylon Pharmaceuticals Drug Discovery Boston, MA 2008
NeoDiagnostix Biotechnology Gaithersburg, MD 0000
To view Celgene’s complete subsidiaries history, request access »

Celgene Exits (75)

Company Name Exit Date Exit Type Exit Size Status Buyers
Oncorus 20-Dec-2019 00000 00000 00 000.00 Completed
  • 17 buyers
Cyteir Therapeutics 15-Oct-2019 00000 00000 00 000.00 Completed
  • 6 buyers
RAPT Therapeutics 18-Jun-2019 00000 00000 00 0000 Completed
  • 6 buyers
BeCareLink 10-May-2019 00000 0000 Completed
  • 2 buyers
Vividion Therapeutics 30-Apr-2019 Later Stage VC 0000 Completed
  • 12 buyers
You’re viewing 5 of 75 exits. Get the full list »

Celgene FAQs

  • When was Celgene founded?

    Celgene was founded in 1986.

  • Who is the founder of Celgene?

    David Stirling Ph.D and Robert Hariri Ph.D are the founders of Celgene.

  • Where is Celgene headquartered?

    Celgene is headquartered in Summit, NJ.

  • What is the size of Celgene?

    Celgene has 8,852 total employees.

  • What industry is Celgene in?

    Celgene’s primary industry is Drug Discovery.

  • Is Celgene a private or public company?

    Celgene is a Private company.

  • What is the current valuation of Celgene?

    The current valuation of Celgene is 000.00.

  • What is Celgene’s current revenue?

    The current revenue for Celgene is 00000.

  • How much funding has Celgene raised over time?

    Celgene has raised $5.01B.

  • Who are Celgene’s investors?

    Asseily Ventures, BB Biotech, CHL Medical Partners, Edelson Technology Partners, and Ridgeback Capital have invested in Celgene.

  • Who are Celgene’s competitors?

    Seagen, Incyte, Gilead Sciences, Merck & Co., and Emmaus Life Sciences are some of the 27 competitors of Celgene.

  • When was Celgene acquired?

    Celgene was acquired on 20-Nov-2019.

  • Who acquired Celgene?

    Celgene was acquired by Bristol-Myers Squibb.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »